“…the practice of using propofol-based [versus volatile anesthetic–based] anesthesia during oncologic surgery with the goal to reduce cancer recurrence or metastatic disease is no longer supported by the available evidence.”
THERE has been growing interest in understanding whether perioperative events such as short-term exposure to a general anesthesia could have a deleterious effect on the oncologic outcomes of cancer surgery by promoting growth and progression of the so-called minimally residual disease. Specifically, it has been hypothesized that the use of volatile anesthetics could be associated with minimally residual disease proliferation, whereas propofol could promote apoptosis and have antimetastatic effects.1 In this issue of Anesthesiology, Makito et al.2 report the results of a retrospective study evaluating the association between overall or recurrence-free survival after cancer surgery and the use of propofol-based total intravenous anesthesia versus volatile anesthetic-based general anesthesia. This cohort study included cancer patients who underwent esophagectomy, gastrectomy, hepatectomy, cholecystectomy, pancreatectomy, colectomy, and rectal cancer surgery.2 Makito et al. have to be commended for conducting this thorough and large-scale retrospective study that included 196,303 oncologic surgery patients in their analysis. Briefly, they showed that the use of propofol-based anesthesia in comparison with volatile-based general anesthesia was not associated with significant improvements in recurrence-free (hazard ratio, 1.00; 95% CI, 0.96 to 1.05; P = 0.94) or overall survival (hazard ratio, 1.01; 95% CI, 0.79 to 1.21; P = 0.77) after adjusting and matching patients for several factors known to impact cancer recurrence.3 The authors also conducted an instrumental variable analyses that indicated a small difference in recurrence-free survival (hazard ratio, 0.92; 95% CI, 0.87 to 0.98; P = 0.01) but not in overall survival (hazard ratio, 1.02; 95% CI, 0.95 to 1.09; P = 0.65).
These findings are in sharp contrast to those from a previous study conducted by Wigmore et al.4 Although both studies were retrospective, the most striking differences are the sample sizes and the source of data. The retrospective study by Makito et al. evaluated 196,303 patients, whereas that by Wigmore evaluated 11,395 patients. Makito et al. used a national administrative registry, whereas Wigmore et al. reported results from a single institution. Findings from single-center studies are known to suffer from external validity. In addition, Makito et al.’s work is in line with a post hoc analysis of a recent international randomized, controlled trial indicating that the use of sevoflurane did not impact breast cancer progression.5 It has been recently suggested that the modulatory effects of general anesthesia on the stress response associated with relatively small surgical procedures such as mastectomies may not matter.5 In fact, Makito et al.’s results suggest that the general anesthesia technique used in more extensive cancer surgeries is also irrelevant to modify factors (i.e., immunity) that influence oncological outcomes.
One of the main strengths of Makito et al.’s study is the large number of patients included in the analysis. This study currently represents the largest retrospective analysis investigating the impact of propofol-based anesthesia versus volatile-based general anesthesia on oncological outcomes using data from the Japanese Diagnosis Procedure Combination database. Although the information contained in that database is standardized, potential weaknesses include the possibility of sampling bias and limited accuracy of information. Makito et al. used a variety of strategies in their statistical analysis to limit confounding and biases. Another strength of the study is that the authors adjusted for multiple factors that are known to affect cancer progression and survival, including the administration of neoadjuvant and adjuvant therapies, perioperative blood transfusions, functional status (Barthel’s index) and postoperative complications. Unfortunately, previous studies had limited information or could not adjust for those important factors, which highlights the superior quality of the study by Makito et al.2
Cancer growth and progression is a complex and highly orchestrated process. The objective of administering adjuvant therapies (i.e., chemotherapy or radiation) is to eliminate or at least control the growth of the minimally residual disease; however, it is poorly understood whether the cellular events triggered during surgery and anesthesia in cancer cells are blunted or exaggerated by adjuvant therapies which can confound the effect of anesthetics on survival outcomes. The in vitro cellular effects of anesthetics on various steps of the metastasis process have been well documented. Unfortunately, well-designed experimental studies indicate that such effects are difficult to reproduce in vivo under experimental conditions that resemble major cancer surgery in humans.6 Perhaps one way to bridge the gap between laboratory in vitro studies and clinical research is the use of humanized mice models. In such models, tumors grow in mice implanted with human hematopoietic stem cells. Then, these cells will colonize the bone marrow and differentiate into the multiple cell lineages that constitute the human immune system. Using humanized mice models, researchers would have the opportunity to test any potential impact of the combination of surgery and anesthetics on cancer progression.7 To date, there is no evidence from randomized clinical trials indicating that propofol-based anesthesia is superior to volatile-based anesthesia in terms of oncological outcomes.
In summary, current evidence suggests that volatile anesthetics do not affect cancer-related outcomes in a negative fashion or impact the survival of surgical cancer patients. In other words, the practice of using propofol-based anesthesia during oncologic surgery with the goal to reduce cancer recurrence or metastatic disease is no longer supported by the available evidence. Therefore, anesthesiologists should not be using propofol-based anesthesia to improve oncologic outcomes.
Supported by grant Nos. R01DK122796, R01DK109574, R01HL133900 from the National Institutes of Health (Bethesda, Maryland; to Dr. Eltzschig).
Dr. Sood reports the following competing interests: Merck (Kenilworth, New Jersey, scientific advisory board), Kiyatec (Greenville, South Carolina, consulting), M-Trap (Oak Ridge, Tennessee, research grant), and BioPath (Bellaire, Texas, shareholder). The other authors declare no competing interests.